NGF enhances the survival of cholinergic neurons in basal forebrain in rats [1–3] and primates [4–7], and phase-I clinical trial of NGF gene therapy for Alzheimer’s disease (AD) provided promising data [8,9]. The gene discussed is NGF; the disease is early-onset autosomal dominant Alzheimer disease.